Pharma and biotech businesses can use CytoReason's vast database and AI-powered platform to find new prospects, shorten trial stages, cut research costs, and boost the chance of approval

Fremont, CA: CytoReason, a leading provider of computational illness models for efficient pharmaceutical research, has extended collaborative arrangements with Pfizer.

"The extension of our collaboration with CytoReason will build upon our existing data science capabilities and further enhance our ability to make data-driven decisions across our portfolio," said Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer, and President, Worldwide Research, Development, and Medical of Pfizer. "We are excited to continue this successful partnership, which has helped us investigate challenging biological questions to potentially inform the development of new therapies for the benefit of patients."

CytoReason is a major technology firm that creates computational illness models. The business acquires confidential data from the pharmaceutical industry and utilizes it to model human illnesses tissue by tissue, cell by cell. Pharma and biotech businesses can use CytoReason's vast database and AI-powered platform to find new prospects, shorten trial stages, cut research costs, and boost the chance of approval.

CytoReason has successfully established itself to be a global leader in human illness computational modeling. The company's interdisciplinary team of 65 outstanding biologists, bioinformaticians, and data engineers has developed a system that allows pharmaceutical and biotech businesses to accelerate medication R&D and provide breakthrough medicines to the people who need them the most.

Since the collaboration's inception in 2019, Pfizer has employed CytoReason's models in its research to improve knowledge of the immune system to produce novel medications. Pfizer has benefited from CytoReason's platform in a variety of R&D initiatives spanning more than 20 illnesses.

"It's exciting to see our technology in the hands of such a stellar group of scientists," said David Harel, CytoReason's CEO and Co-founder. "Our work with the Pfizer team has demonstrated how our computational models can potentially match the right treatment to the right patient groups across multiple therapeutic areas. Through this collaboration and our growing customer base worldwide, we aim to establish our platform as the gold standard for drug discovery, development, and portfolio management."